TY - JOUR T1 - UDCA and INT-777 suppress cardiac fibrosis triggered by IL-11 through involvement of TGR5 JF - medRxiv DO - 10.1101/2022.05.11.22274945 SP - 2022.05.11.22274945 AU - B. Reilly-O’Donnell AU - E. Ferraro AU - R. Tikhomirov AU - R. Nunez-Toldra AU - A. Shchendrygina AU - L. Patel AU - Y. Wu AU - A. L. Mitchell AU - A. Endo AU - L. Adorini AU - R. A. Chowdhury AU - P. K. Srivastava AU - F. S. Ng AU - C. M. Terracciano AU - C. Williamson AU - J. Gorelik Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/16/2022.05.11.22274945.abstract N2 - Cardiac fibrosis occurs in a wide range of cardiac diseases and is characterised by the transdifferentiation of cardiac fibroblasts (FB) into myofibroblasts (MFB). Myofibroblasts produce large quantities of extracellular matrix proteins, resulting in myocardial scar. The antifibrotic effect of the bile acid ursodeoxycholic acid (UDCA) is established in cases of liver fibrosis but not the adult myocardium.Our hypothesis is: UDCA is antifibrotic in the adult heart, mediated by the membrane bile acid receptor Takeda G protein-coupled receptor 5 (TGR5).We constructed a predictive network of fibrosis using RNA-seq datasets. We found that UDCA and it’s analogue INT-777, both reduced MFB markers in rat and human FBs and living myocardial slices (LMS). Utilising a knock-out mouse model, we show that the antifibrotic effect of UDCA is mediated by TGR5. Finally, we performed RNA-seq upon UDCA-treated human FB and integrated with our network of fibrosis, establishing the mechanism of TGR5 agonists.Competing Interest StatementDr Luciano Adorini is a consultant for Intercept Pharmaceuticals.Funding StatementThis research was funded by Heart Research UK (RG2666/17/19)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All animal experiments were performed in the United Kingdom (UK) according to the standards for the care and use of animal subjects determined by the UK Home Office (ASPA1986 Amendments Regulations 2012) incorporating the EU directive 2010/63/EU. The animal welfare and ethical review body committee of Imperial College London approved all protocols. This study was supported by the supply of human failing hearts from the Cardiovascular Research Centre Biobank, at the Royal Brompton and Harefield hospitals (NRES Ethics number for biobank samples: 09/H0504/104+5, Biobank approval number: NP001-06-2015 and MED_CT_17_079) and donor hearts from NHS Blood and Transplant (NRES Ethics number 16/LO/1568, NHS Blood and Transplant study numbers 67 and 106). All procedures described were carried out in accordance with the Human Tissue Act 2004.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials. ER -